Figure 10.2.

Biodistribution of targeted and nontargeted nanoparticles for the antigens transferrin receptor (TfR; Bartlett et al., 2007), HER2 (Kirpotin et al., 2006; Lub-de Hooge et al., 2004), EGFR (Mamot et al., 2005; Ping Li et al., 2008), EpCAM (Goldrosen et al., 1990; Hussain et al., 2007), CD19 (Lopes de Menezes et al., 1998), PSMA (Gu et al., 2008; Smith-Jones et al., 2003), and the folate receptor (FR; Coliva et al., 2005; Gabizon et al., 2003). Data are for 24-h postinjection in all cases, and all of the nanoparticles were ~100nm in diameter. Negative controls for the nanoparticle studies are generally irrelevant ligands. In the panel on the right, a compartmental model is used to predict what proportion of observed tumor uptake at 24h could be attained via the enhanced permeability and retention (EPR) effect without the use of ligand targeting (Schmidt and Wittrup, 2009).